Substance / Medication

Olaratumab

Overview

Active Ingredient
olaratumab
RxNorm CUI
1855735

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas.
Hammer Kathryn J, Copeland Vanessa C, Loggers Elizabeth T et al. · Am J Clin Oncol · 2020
PMID: 32235164Observational
Olaratumab for the treatment of advanced soft tissue sarcoma.
Okuno Scott H, Maran Avudaiappan, Robinson Steven I · Expert Rev Anticancer Ther · 2017
PMID: 28862476Observational
Olaratumab for advanced soft tissue sarcoma.
Tobias Alexander, O'brien Michael P, Agulnik Mark · Expert Rev Clin Pharmacol · 2017
PMID: 28447475Observational
Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?
Kyriazoglou Anastasios, Koutsoukos Konstantinos, Zagouri Flora et al. · Ther Clin Risk Manag · 2020
PMID: 32161464Case ReportFull text (PMC)
PDGFRα monoclonal antibody: Assessment of toxicity in juvenile mice administered a murine surrogate antibody of olaratumab.
Baracani Ronee, Bhaskaran Manoj, Davis Sarah M et al. · Birth Defects Res · 2023
PMID: 36916488Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Olaratumab (substance)
SNOMED CT
723523007
UMLS CUI
C2698152
RxNorm CUI
1855735

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.